Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Lorcaserin. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C known ✓ | P28335 | 20/20 | 0.97 |
| ▸ | HTR2A | P28223 | 20/20 | 0.97 |
| ▸ | HTR2B | P41595 | 18/20 | 0.97 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.97 |
| ▸ | HTR1A | P08908 | 1/20 | 0.97 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.97 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.97 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.97 |
| ▸ | CNR1 | P21554 | 1/20 | 0.97 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.97 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.97 |
| ▸ | HRH1 | P35367 | 1/20 | 0.97 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.97 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Lorcaserin SCHEMBL1094953 | 0.98 | HTR2A (1.00) | HTR2AHTR2CHTR2BADRB1HTR1A | |
| Lorcaserin SCHEMBL29349440 | 0.98 | HTR2A (1.00) | HTR2AHTR2CHTR2BADRB1HTR1A | |
| Lorcaserin SCHEMBL169382 | 0.98 | HTR2A (1.00) | HTR2AHTR2CHTR2BADRB1HTR1A | |
| Lorcaserin SCHEMBL170848 | 0.98 | HTR2A (1.00) | HTR2AHTR2CHTR2BADRB1HTR1A | |
| Lorcaserin SCHEMBL5946555 | 0.98 | HTR2A (1.00) | HTR2AHTR2CHTR2BADRB1HTR1A | |
| Lorcaserin SCHEMBL1954700 | 0.97 | HTR2A (0.97) | HTR2AHTR2CHTR2BADRB1HTR1A | |
| Lorcaserin SCHEMBL174044 | 0.97 | HTR2A (0.97) | HTR2AHTR2CHTR2BADRB1HTR1A | |
| Lorcaserin SCHEMBL174046 | 0.97 | HTR2A (0.97) | HTR2AHTR2CHTR2BADRB1HTR1A | |
| Lorcaserin SCHEMBL16672993 | 0.97 | HTR2A (0.97) | HTR2AHTR2CHTR2BADRB1HTR1A | |
| Lorcaserin SCHEMBL173808 | 0.97 | HTR2A (0.97) | HTR2AHTR2CHTR2BADRB1HTR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140148442-A1 | FAST-DISSOLVE DOSAGE FORMS OF 5-HT2C AGONISTS | ARENA PHARMACEUTICALS, INC. | 2014-05-29 | — | — | US | claimed |
| EP-2611781-A1 | FAST-DISSOLVE DOSAGE FORMS OF 5-HT2C AGONISTS | Arena Pharmaceuticals, Inc. (US) | 2013-07-10 | — | — | EP | claimed |
| WO-2012030951-A1 | FAST-DISSOLVE DOSAGE FORMS OF 5-HT2C AGONISTS | ARENA PHARMACEUTICALS, INC. (US) | 2012-03-08 | — | — | WO | claimed |
| US-10463676-B2 | Modified-release dosage forms of 5-HT2C agonists useful for weight management | ARENA PHARMACEUTICALS, INC. (US) | 2019-11-05 | — | — | US | disclosed |
| US-20190275055-A1 | Modified-Release Dosage Forms of 5-Ht2c Agonists Useful for Weight Management | ARENA PHARMACEUTICALS, INC. | 2019-09-12 | — | — | US | disclosed |
| EP-3485878-A1 | MODIFIED-RELEASE DOSAGE FORMS OF 5-HT2C AGONISTS USEFUL FOR WEIGHT MANAGEMENT | Arena Pharmaceuticals, Inc. (US) | 2019-05-22 | — | — | EP | disclosed |
| US-10226471-B2 | Modified-release dosage forms of 5-HT2C agonists useful for weight management | ARENA PHARMACEUTICALS, INC. (US) | 2019-03-12 | — | — | US | disclosed |
| EP-2611427-B1 | MODIFIED-RELEASE DOSAGE FORMS OF 5-HT2C AGONISTS USEFUL FOR WEIGHT MANAGEMENT | ARENA PHARM INC (US) | 2018-10-17 | — | — | EP | disclosed |
| US-9770455-B2 | Administration of an anti-obesity compound to individuals with renal impairment | ARENA PHARMACEUTICALS, INC. (US) | 2017-09-26 | — | — | US | disclosed |
| US-20170246179-A1 | MODIFIED-RELEASE DOSAGE FORMS OF 5-HT2C AGONISTS USEFUL FOR WEIGHT MANAGEMENT | ARENA PHARMACEUTICALS, INC. | 2017-08-31 | — | — | US | disclosed |
| US-20170239263-A1 | METHOD OF WEIGHT MANAGEMENT | ARENA PHARMACEUTICALS, INC. | 2017-08-24 | — | — | US | disclosed |
| US-20130267500-A1 | 5-HT2C RECEPTOR AGONISTS IN THE TREATMENT OF DISORDERS AMELIORATED BY REDUCTION OF NOREPINEPHRINE LEVEL | ARENA PHARMACEUTICALS, INC. | 2013-10-10 | — | — | US | disclosed |
| EP-2611449-A1 | ADMINISTRATION OF LORCASERIN TO INDIVIDUALS WITH RENAL IMPAIRMENT | Arena Pharmaceuticals, Inc. (US) | 2013-07-10 | — | — | EP | disclosed |
| EP-2611781-A1 | FAST-DISSOLVE DOSAGE FORMS OF 5-HT2C AGONISTS | Arena Pharmaceuticals, Inc. (US) | 2013-07-10 | — | — | EP | disclosed |
| EP-2611427-A2 | MODIFIED-RELEASE DOSAGE FORMS OF 5-HT2C AGONISTS USEFUL FOR WEIGHT MANAGEMENT& xA; | Arena Pharmaceuticals, Inc. (US) | 2013-07-10 | — | — | EP | disclosed |
| US-20120252787-A1 | ADMINISTRATION OF AN ANTI-OBESITY COMPOUND TO INDIVIDUALS WITH RENAL IMPAIRMENT | ARENA PHARMACEUTICALS, INC. | 2012-10-04 | — | — | US | disclosed |
| WO-2012030953-A1 | 5-HT2C RECEPTOR AGONISTS IN THE TREATMENT OF DISORDERS AMELIORATED BY REDUCTION OF NOREPINEPHRINE LEVEL | ARENA PHARMACEUTICALS, INC. (US) | 2012-03-08 | — | — | WO | disclosed |
| WO-2012030951-A1 | FAST-DISSOLVE DOSAGE FORMS OF 5-HT2C AGONISTS | ARENA PHARMACEUTICALS, INC. (US) | 2012-03-08 | — | — | WO | disclosed |
| WO-2012030927-A2 | MODIFIED-RELEASE DOSAGE FORMS OF 5-HT2C AGONISTS USEFUL FOR WEIGHT MANAGEMENT | ARENA PHARMACEUTICALS, INC. (US) | 2012-03-08 | — | — | WO | disclosed |
| WO-2012030939-A1 | ADMINISTRATION OF LORCASERIN TO INDIVIDUALS WITH RENAL IMPAIRMENT | ARENA PHARMACEUTICALS, INC. (US) | 2012-03-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170246179-A1 | MODIFIED-RELEASE DOSAGE FORMS OF 5-HT2C AGONISTS USEFUL FOR WEIGHT MANAGEMENT | HTR2C, HTR2A, HTR3C | HTR2C 1/4885HTR2A 2/4885HTR2B 8/4885 |
| US-10463676-B2 | Modified-release dosage forms of 5-HT2C agonists useful for weight management | HTR2C, HTR2A, HTR3C | HTR2C 1/4885HTR2A 2/4885HTR2B 8/4885 |
| US-20120252787-A1 | ADMINISTRATION OF AN ANTI-OBESITY COMPOUND TO INDIVIDUALS WITH RENAL IMPAIRMENT | REN, GLS, GPR119 | HTR2C 155/4885HTR2A 235/4885HTR2B 700/4885 |
| US-10226471-B2 | Modified-release dosage forms of 5-HT2C agonists useful for weight management | HTR2C, HTR2A, HTR3C | HTR2C 1/4885HTR2A 2/4885HTR2B 8/4885 |
| US-20140148442-A1 | FAST-DISSOLVE DOSAGE FORMS OF 5-HT2C AGONISTS | HTR2C, HTR2A, HTR1A | HTR2C 1/4885HTR2A 2/4885HTR2B 11/4885 |
| US-20170239263-A1 | METHOD OF WEIGHT MANAGEMENT | GCG, CEL, GCKR | HTR2C 150/4885HTR2A 345/4885HTR2B 312/4885 |
| US-20190275055-A1 | Modified-Release Dosage Forms of 5-Ht2c Agonists Useful for Weight Management | HTR2C, HTR2A, HTR3C | HTR2C 1/4885HTR2A 2/4885HTR2B 8/4885 |
| US-20130267500-A1 | 5-HT2C RECEPTOR AGONISTS IN THE TREATMENT OF DISORDERS AMELIORATED BY REDUCTION OF NOREPINEPHRINE LEVEL | ADRA2C, HTR2C, HTR2A | HTR2C 2/4885HTR2A 3/4885HTR2B 8/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.